Limited coverage drugs – entecavir
Last updated on October 7, 2022
|
Generic name |
entecavir |
|---|---|
|
Strength |
0.5 mg |
|
Form |
tablet |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of chronic hepatitis B in treatment-naïve patients, if the Special Authority request includes all required lab work (as detailed in the HLTH 5372 Chronic Hepatitis B form). |
Indefinite |
Practitioner exemptions
- None
Special notes
- In exceptional cases, PharmaCare may consider requests for coverage of patients who do not meet the established criteria, if the physician provides additional documentation supporting the patient’s specific clinical need. The Hepatitis Drug Benefit Adjudication Advisory Committee reviews exceptional case requests